Archives

  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06

    • Metformin HCl Reduces Vocal Fold Fibrosis via AMPK Modulatio

    2026-06-12

    Metformin HCl Reduces Vocal Fold Fibrosis via AMPK Modulation

    Study Background and Research Question

    Vocal fold fibrosis represents a persistent clinical challenge characterized by abnormal extracellular matrix deposition following injury, leading to impaired vocal quality and function. Current interventions—ranging from voice therapy and corticosteroid injections to surgical procedures—frequently yield incomplete restoration of vocal fold structure, and may introduce further risks or require repeated administrations. Given metformin’s established efficacy in modulating fibrotic and metabolic pathways in other tissues, Cai et al. (2025) hypothesized that Metformin Hydrochloride (Metformin HCl) could attenuate fibrosis in vocal folds through activation of the AMP-activated protein kinase (AMPK) signaling pathway.

    Key Innovation from the Reference Study

    A central innovation of this study lies in applying Metformin HCl—traditionally used as an antidiabetic agent and AMPK pathway modulator—to a clinically relevant model of vocal fold fibrosis. The research evaluates both in vivo effects in a rabbit vocal fold injury model and in vitro mechanisms using primary fibroblasts, focusing on AMPK pathway activation as a mechanistic axis. This approach bridges metabolic and fibrotic research, clarifying how inhibition of hepatic gluconeogenesis and attenuation of lipid biosynthesis—core actions of metformin—may also suppress fibrotic remodeling in laryngeal tissue.

    Methods and Experimental Design Insights

    The authors utilized a well-characterized rabbit model, inducing standardized vocal fold injury in 24 New Zealand White rabbits. Two weeks post-injury, animals received intraperitoneal metformin at 250 mg/kg. Four weeks post-injury, excised vocal folds were analyzed histologically (Masson’s trichrome staining), and by immunohistochemistry, qPCR, and Western blotting for markers of fibrosis and pathway activation. Complementary in vitro experiments involved treating primary vocal fold fibroblasts with metformin (10 μM) in the presence or absence of TGF-β1 (10 ng/mL), a key pro-fibrotic cytokine. Compound C (10 μM), a selective AMPK inhibitor, was used to dissect the pathway specificity of metformin’s effects. Collagen type I alpha 1 (COL1A1) and alpha-smooth muscle actin (α-SMA) were quantified as canonical markers of fibrosis, alongside TGF-β signaling intermediates Smad2 and Smad3.

    Protocol Parameters

    • In vivo metformin dosing: 250 mg/kg, intraperitoneally, administered two weeks after vocal fold injury in rabbits, continuing until sample collection at four weeks.
    • In vitro metformin treatment: 10 μM, with or without 10 ng/mL TGF-β1, applied to primary rabbit vocal fold fibroblasts.
    • AMPK inhibition control: Compound C at 10 μM to selectively inhibit AMPK signaling in vitro.
    • Fibrosis marker quantification: Assessment of COL1A1 and α-SMA expression by qPCR, Western blot, and immunohistochemistry.

    Core Findings and Why They Matter

    According to the reference study, metformin treatment significantly reduced collagen deposition and improved the structural integrity of the vocal fold lamina compared to untreated controls. Molecular analyses revealed decreased expression of COL1A1 and α-SMA, both in vivo and in vitro, indicating attenuation of myofibroblast differentiation and extracellular matrix accumulation. Notably, metformin activated AMPK in vocal fold fibroblasts, leading to downstream suppression of TGF-β, Smad2, and Smad3—key mediators of profibrotic signaling. The use of Compound C, which abolished the antifibrotic effects of metformin, further confirmed the centrality of AMPK activation in this context. These results suggest that metformin’s action as a fatty acid oxidation promoter and lipid biosynthesis attenuator is mechanistically linked to its ability to modulate fibrotic pathways in non-metabolic tissues, expanding its research utility beyond classic glucose metabolism models.

    Comparison with Existing Internal Articles

    Recent internal resources have examined the role of Metformin HCl in various fibrotic and ossification contexts. For example, "Metformin Suppresses Tendon Ossification via Nr4a1/Wnt/β-catenin Inhibition" demonstrated that metformin modulates tendon fibrosis and ossification through suppression of the Wnt/β-catenin pathway. Similarly, "Metformin Hydrochloride: Deep Mechanisms Beyond Glucose Metabolism" highlighted AMPK's centrality in diverse tissue contexts, including bone and metabolic disorders. The current study extends these mechanistic insights into the laryngeal domain, reinforcing metformin's position as a versatile AMPK signaling pathway modulator. Unlike prior musculoskeletal studies that emphasized ossification, the Cai et al. study is the first to directly demonstrate antifibrotic effects of metformin in vocal fold tissue, specifically linking AMPK activation to downregulation of TGF-β/Smad2/3 signaling. This highlights a growing consensus that metformin’s effects on fibrosis may be generalizable across soft tissue types, provided AMPK pathway engagement is achieved.

    Limitations and Transferability

    While the findings are compelling, several limitations should be considered. The rabbit model, while physiologically relevant, may not fully recapitulate human vocal fold biology or the chronicity of scarring seen clinically. The study also focuses on relatively acute time windows (2–4 weeks post-injury), leaving longer-term remodeling effects unexplored. Additionally, the high intraperitoneal dosing used in rabbits may not directly translate to human or other animal models, necessitating careful dose optimization in translational studies. Pathway-specificity was supported by use of Compound C, but off-target effects or contributions from other metabolic regulators cannot be completely excluded. Further, while AMPK activation is implicated as a central antifibrotic mechanism, the role of secondary pathways (such as inhibition of hepatic gluconeogenesis or changes in cellular redox status) remains to be clarified in vocal fold tissue.

    Research Support Resources

    Researchers interested in exploring similar workflows or extending this line of investigation can source research-grade Metformin Hydrochloride (Metformin HCl) (SKU B1970) from APExBIO. This compound is widely used in studies of AMPK signaling, hepatic gluconeogenesis inhibition, and fibrosis modulation. For best results, follow established solubility and storage protocols as outlined in the product information. The findings of Cai et al. underscore the utility of Metformin HCl for dissecting AMPK-driven fibrotic mechanisms in diverse tissue models.